These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 23634866)
1. Reply: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup? Noth I; Olman M; Am J Respir Crit Care Med; 2013 May; 187(9):1030. PubMed ID: 23634866 [No Abstract] [Full Text] [Related]
2. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup? Kubo H; Yanai M; Azuma A Am J Respir Crit Care Med; 2013 May; 187(9):1029-30. PubMed ID: 23634865 [No Abstract] [Full Text] [Related]
3. Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? : a reply to Tzouvelekis. Noth I; Olman M; Am J Respir Crit Care Med; 2013 Jan; 187(2):214. PubMed ID: 23441317 [No Abstract] [Full Text] [Related]
4. Reply: rationale for anticoagulant therapy of pulmonary fibrosis. Noth I; Olman MA Am J Respir Crit Care Med; 2014 Feb; 189(3):363. PubMed ID: 24484338 [No Abstract] [Full Text] [Related]
5. Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis? Bendstrup E; Hilberg O Am J Respir Crit Care Med; 2012 Oct; 186(7):693; author reply 693-4. PubMed ID: 23027854 [No Abstract] [Full Text] [Related]
6. Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? Tzouvelekis A; Margaritopoulos G; Loukides S; Bouros D Am J Respir Crit Care Med; 2013 Jan; 187(2):213-4. PubMed ID: 23322796 [No Abstract] [Full Text] [Related]
7. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Noth I; Anstrom KJ; Calvert SB; de Andrade J; Flaherty KR; Glazer C; Kaner RJ; Olman MA; Am J Respir Crit Care Med; 2012 Jul; 186(1):88-95. PubMed ID: 22561965 [TBL] [Abstract][Full Text] [Related]
8. Rationale for anticoagulant therapy of pulmonary fibrosis. Bogatkevich GS; Nietert PJ; Silver RM; Highland KB Am J Respir Crit Care Med; 2014 Feb; 189(3):362-3. PubMed ID: 24484337 [No Abstract] [Full Text] [Related]
9. Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease. Müller-Quernheim J; Wells A Am J Respir Crit Care Med; 2012 Jul; 186(1):5-7. PubMed ID: 22753682 [No Abstract] [Full Text] [Related]
10. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Kondoh Y; Azuma A; Inoue Y; Ogura T; Sakamoto S; Tsushima K; Johkoh T; Fujimoto K; Ichikado K; Matsuzawa Y; Saito T; Kishi K; Tomii K; Sakamoto N; Aoshima M; Araya J; Izumi S; Arita M; Abe M; Yamauchi H; Shindoh J; Suda T; Okamoto M; Ebina M; Yamada Y; Tohda Y; Kawamura T; Taguchi Y; Ishii H; Hashimoto N; Abe S; Taniguchi H; Tagawa J; Bessho K; Yamamori N; Homma S Am J Respir Crit Care Med; 2020 May; 201(9):1110-1119. PubMed ID: 31917621 [No Abstract] [Full Text] [Related]
11. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Kreuter M; Wijsenbeek MS; Vasakova M; Spagnolo P; Kolb M; Costabel U; Weycker D; Kirchgaessler KU; Maher TM Eur Respir J; 2016 Jun; 47(6):1776-84. PubMed ID: 27103382 [TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism in people with idiopathic pulmonary fibrosis: a population-based study. Dalleywater W; Powell HA; Fogarty AW; Hubbard RB; Navaratnam V Eur Respir J; 2014 Dec; 44(6):1714-5. PubMed ID: 25323238 [No Abstract] [Full Text] [Related]
13. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914 [TBL] [Abstract][Full Text] [Related]
14. Reply: Heparin versus Warfarin in Interstitial Pulmonary Fibrosis: The Quest for the Right Anticoagulant Continues. Margaritopoulos GA; Antoniou KM Am J Respir Crit Care Med; 2017 Jan; 195(1):142-143. PubMed ID: 28035862 [No Abstract] [Full Text] [Related]
15. We should prohibit warfarin in idiopathic pulmonary fibrosis. Alagha K; Secq V; Pahus L; Sofalvi T; Palot A; Bourdin A; Chanez P Am J Respir Crit Care Med; 2015 Apr; 191(8):958-60. PubMed ID: 25876206 [No Abstract] [Full Text] [Related]
16. [Anticoagulant therapy for idiopathic pulmonary fibrosis]. Kubo H Rev Port Pneumol; 2005; 11(6):591-2. PubMed ID: 16521238 [No Abstract] [Full Text] [Related]
17. [Prolongation of oral anticoagulant treatment for eighteen months versus placebo at the decline of a first episode of idiopathic pulmonary embolism treated for six months: a randomized, multicentric, double blind trial. 2006 National PHRC (Hospital clinical research programme): "PADIS-EP/Prolongation of anticoagulant treatment for 18 months for a first episode of PE initially treated for 6 months"]. Couturaud F Rev Pneumol Clin; 2008 Dec; 64(6):332-6. PubMed ID: 19084215 [No Abstract] [Full Text] [Related]
18. Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis. Naqvi SF; Sohail AH; Lakhani DA; Maurer J; Sofka S; Hadi YB Pulm Med; 2021; 2021():3432362. PubMed ID: 34868680 [TBL] [Abstract][Full Text] [Related]